North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane
Micro-Abstract Angiogenesis is an established target in metastatic breast cancer (MBC). Aflibercept (vascular endothelial growth factor [VEGF]-trap) is a humanized fusion protein which binds VEGF-A, VEGF-B, and placental growth factors PIGF-1, and PIGF-2. A phase II study was conducted to test the s...
Saved in:
Published in: | Clinical breast cancer 2012-12, Vol.12 (6), p.387-391 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | eng |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Micro-Abstract Angiogenesis is an established target in metastatic breast cancer (MBC). Aflibercept (vascular endothelial growth factor [VEGF]-trap) is a humanized fusion protein which binds VEGF-A, VEGF-B, and placental growth factors PIGF-1, and PIGF-2. A phase II study was conducted to test the safety and efficacy of aflibercept in patients with MBC. Though safety was acceptable, aflibercept did not demonstrate sufficient activity to warrant further study, as a single agent, in this patient population. |
---|---|
ISSN: | 1526-8209 1938-0666 |